Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Tumor Immunotherapy01:27

Tumor Immunotherapy

472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Vaccines01:30

Cancer Vaccines

337
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
337
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
  1. ホーム
  2. 銅セラート標的 外部化フォスファディチルセリンはpd-l1発現を抑制し,がん免疫療法を強化する
  1. ホーム
  2. 銅セラート標的 外部化フォスファディチルセリンはpd-l1発現を抑制し,がん免疫療法を強化する

関連する実験動画

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

236

銅セラート標的 外部化フォスファディチルセリンはPD-L1発現を抑制し,がん免疫療法を強化する

Fan Gao1,2, Wei You2, Lei Zhang1

  • 1Department of Pharmacy, The First Affiliated Hospital of USTC; Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparation and Clinical Pharmacy, Hefei, Anhui 230026, China.

Journal of the American Chemical Society
|January 11, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

新しい銅ケラートは,癌細胞に外部化されたフォスファディチルセリン (PS) を標的とし,免疫反応を強化し,PD-1/PD-L1療法に対する抵抗を克服します. この抗体独立戦略は 効果的ながん免疫療法の見込みを示しています

さらに関連する動画

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.4K

関連する実験動画

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

236
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.4K

科学分野:

  • 免疫学
  • 腫瘍学
  • 材料科学

背景:

  • PD- 1/ PD- L1 免疫チェックポイント阻害剤は限られた臨床反応を示し,多くの患者で耐性が見られた.
  • 癌細胞に外部化されたフォスファディチルセリン (PS) は,PD- L1阻害療法に対する免疫抑制と抵抗に寄与する.

研究 の 目的:

  • 外部化PSを標的とした新しい戦略を開発し,がんの免疫療法における抵抗を克服する.
  • 抗腫瘍免疫反応の強化におけるファルネゾール尾のテルピリジン-Cu複合体の有効性を調査する.

主な方法:

  • 外部化PSをがん細胞に標的として,銅ケラート (ターピリジン-Cu複合体とファルネゾール尾) を合成した.
  • 樹状細胞の成熟,T細胞の増殖,腫瘍の浸透,PD- L1発現に対する化合物の効果を評価した.
  • 腫瘍の根絶と免疫学的記憶は,大腸直腸がんとメラノーマがんのマウスモデルで評価されました.

主要な成果:

  • PSを標的とした銅酸は, dendritic 細胞の成熟と T 細胞の反応を促した.
  • このアプローチはPD- L1発現を有意に抑制し,T細胞媒介免疫を強めた.
  • 結腸直腸腫瘍や黒色腫のマウスの70%以上は完全に根絶され,免疫的記憶が発達した.

結論:

  • 外部化PSを新しい銅ケラートで標的化することは,がん免疫療法における抗体独立戦略として有望である.
  • このアプローチは,抗腫瘍免疫反応を強化することで,現在のチェックポイントブロック治療の限界を克服することができます.
  • 開発された化合物は,免疫学的記憶を効果的に誘導し,臨床前モデルで有意な腫瘍根絶を達成します.